Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-01-31
Clinical Trial Update: Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. [Phase 2]
Phase 2 trial of anlotinib combined with niraparib for platinum-resistant recurrent clear cell ovarian cancer has been completed.